Physician profile
Patrick J Sanchez
NPI 1669812087
$8,160.41
in general payments reported to CMS, 2019-2025
32 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $641 · 2021: $1,776 · 2022: $1,646 · 2023: $1,327 · 2024: $1,179 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,728.19 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $775.78 | 2019-2024 | Xifaxan, Trulance |
| Celgene Corporation | $752.03 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $651.58 | 2019-2025 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $595.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $511.78 | 2019-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $409.86 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $272.90 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $214.21 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $165.97 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $128.42 | 2020-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $125.04 | 2024-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $117.17 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $92.07 | 2023-2024 | Ibsrela |
| Gilead Sciences, INC. | $91.57 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $89.18 | 2023-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $63.99 | 2022-2024 | Cimzia, Rebyota, Clenpiq |
| Alnylam Pharmaceuticals INC. | $57.11 | 2021 | |
| Evoke Pharma, INC. | $38.94 | 2022-2024 | Gimoti |
| Amgen INC. | $35.42 | 2021 | |
| Axonics, INC. | $33.76 | 2021-2024 | Axonics |
| Lilly USA, LLC | $31.72 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $31.21 | 2021-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $30.72 | 2025 | Rezdiffra |
| Endogastric Solutions, INC | $24.54 | 2023 | Esophyx |
| Corcept Therapeutics | $23.87 | 2019 | |
| Mauna Kea Technologies, INC. | $14.80 | 2020 | |
| Genzyme Corporation | $14.21 | 2025 | |
| Alfasigma USA, INC. | $14.02 | 2020 | |
| Allergan, INC. | $13.04 | 2019 | |
| Shire North American Group INC | $11.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,605.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.